Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment.

about

Identification of novel systemic sclerosis biomarkers employing aptamer proteomic analysis.Unmet Needs in Systemic Sclerosis Understanding and Treatment: the Knowledge Gaps from a Scientist's, Clinician's, and Patient's Perspective.

P2860

Q47400242-CEE3AC6B-9451-4CDB-92B6-40797FEE7DA4 Q50230077-8808116D-CC86-4093-9613-015A5A375D60

P2860

Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment.

Item

http://www.wikidata.org/entity/Q40292542

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Proteomic Analysis of Sera fro ...... g Imatinib Mesylate Treatment.

@en

type

Item

label

Proteomic Analysis of Sera fro ...... g Imatinib Mesylate Treatment.

@en

prefLabel

Proteomic Analysis of Sera fro ...... g Imatinib Mesylate Treatment.

@en

P1476

Proteomic Analysis of Sera fro ...... ng Imatinib Mesylate Treatment

@en

P2093

D James Haddon

http://www.w3.org/2001/XMLSchema#string

Jessica K Gordon

http://www.w3.org/2001/XMLSchema#string

Justin A Jarrell

http://www.w3.org/2001/XMLSchema#string

Lorinda S Chung

http://www.w3.org/2001/XMLSchema#string

Paul J Utz

http://www.w3.org/2001/XMLSchema#string

Robert F Spiera

http://www.w3.org/2001/XMLSchema#string

P2860

Significance analysis of microarrays applied to the ionizing radiation response

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

Correlations between changes in cytokines and clinical outcomes for early phase (proof of concept) trials in active diffuse systemic sclerosis using data from an imatinib study.

Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis

Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study.

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

Risk factors for ANA positivity in healthy persons

Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being.

A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease

Increased plasma soluble CD40 ligand concentrations in systemic sclerosis and association with pulmonary arterial hypertension and digital ulcers.

P304

631-638

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3899/JRHEUM.160833

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hannah E Wand

P577

2017-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28298564

http://www.w3.org/2001/XMLSchema#string

P932

5860882

http://www.w3.org/2001/XMLSchema#string

Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment.

about

P2860

P2860

Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932